Kolaviron attenuated arsenic acid induced-cardiorenal dysfunction via regulation of ROS, C-reactive proteins (CRP), cardiac troponin I (CTnI) and BCL2

Ademola Adetokunbo Oyagbemia, Temidayo Olutayo Omobowaleb, Ebunoluwa Racheal Asenugac, John Olusoji Abiola, Adeolu Alex Adedapo, Momoh Audu Yakubud

Department of Veterinary Physiology, Biochemistry and Pharmacology, Faculty of Veterinary Medicine, University of Ibadan, Nigeria
Department of Veterinary Medicine, Faculty of Veterinary Medicine, University of Ibadan, Nigeria
Department of Veterinary Biochemistry, Faculty of Veterinary Medicine, University of Benin, Nigeria
Department of Environmental & Interdisciplinary Sciences, College of Science, Engineering & Technology, NSB303, Vascular Biology Unit, Centre for Cardiovascular Diseases, COPHS, Texas Southern University, Houston, TX, USA

ARTICLE INFO
Article history:
Received 14 November 2016
Received in revised form 24 April 2017
Accepted 11 May 2017
Available online 7 December 2017

Keywords:
Kolaviron
Arsenic acid
Oxidative stress
Cardiovascular dysfunction
Chemoprevention

Abstract
Arsenic acid is one of the abundant environmental pollutants present in soil, water and the air. Undoubtedly, it has found its way to the food chain in which humans and animals are the final targets thereby causing arrays of disease conditions including cardiovascular and renal dysfunction. Hence, the use of phytochemicals present in medicinal plants has gained global acceptance as chemotherapeutic agents that can prevent, ameliorate, reverse or treat diseases. From our study, arsenic acid intoxication led to significant increase in heart rate (HR), QRS, together with prolonged QT and QTc interval. However, Kolaviron (KV) at the dosage of 100 and 200 mg/kg body weight reversed the aforementioned electrocardiographic (ECG) changes. KV pre-treatment also ameliorated cardiorenal dysfunction via significant reduction in cardiac and renal markers of oxidative stress such as malondialdehyde, hydrogen peroxide generation, myeloperoxidase activity and nitric oxide contents. Immunohistochemistry revealed expressions of renal C-reactive proteins (CRP) and expressions of anti-apoptotic protein BCL2 in KV treated rats. Furthermore, cardiac troponin I (CTnI) expressions were lower in KV treated rats. Taken together, KV mitigated arsenic-acid induced cardiovascular dysfunction via up-regulation of antioxidant defense system and down-regulation of inflammatory and apoptotic signaling pathways.

1. Introduction
Arsenic has been recorded as one of the ubiquitous environmental pollutants that nearly affect all organs in the body. In a study elsewhere, exposures to inorganic arsenic (iAs) in drinking water was found to be associated with both carcinogenic and non-carcinogenic effects. Epidemiological studies revealed that population can be exposed to inorganic arsenic via water and also through consumption of food with higher arsenic concentrations. Several other epidemiological studies reported associations between arsenic exposure and skin, bladder, lung, liver and kidney cancer as well as cardiovascular diseases, diabetes reproductive and developmental effects. The trivalent methylated arsenicals are known to be responsible for the toxicity and carcinogenicity of environmental arsenic toxicity. Furthermore, both inorganic and organic trivalent arsenicals have been shown to be more potent toxicants than pentavalent forms of arsenic acid. However, mechanism of arsenic-induced cardiac abnormalities has been linked to NF-

* Corresponding author. Fax: +234 28103043.
E-mail address: bukitayo_omobowale@yahoo.com (T.O. Omobowale).

Peer review under responsibility of The Center for Food and Biomolecules, National Taiwan University.

http://dx.doi.org/10.1016/j.jtcme.2017.05.003
2225-4110/© 2017 Center for Food and Biomolecules, National Taiwan University. Production and hosting by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
kappaB activation via IKK, p38 and JNK MAPK signaling pathways respectively. Also, exposure to arsenic is influenced by the environmental factors together with individuals exhibiting different urinary arsenic metabolism patterns. In an in vivo experiment, animals exposed to NaAsO2 (10 mg/kg) orally for 10 days were found to have significantly inhibited superoxide dismutase, catalase, glutathione-S-transferase, glutathione peroxidase, glutathione reductase and reduced glutathione level in myocardial tissues of rats. In addition, NaAsO2 was found to significantly increase oxidized glutathione (GSS), malondialdehyde (MDA) and protein carbonyl (PCO) content in myocardial tissues. Furthermore, hepato-renal damage and the influence of arsenic-induced DNA fragmentation of hepatic and renal tissues has also been documented. Recently, arsenic exposure has been shown to be higher in meat and folate consumption, diet rich in green leafy and red-orange vegetables and eggs.

Kolv airon (KV) is a biflavonoid complex from the methanol extract from Garcinia kola seed. The antioxidant and immunomodulatory properties of KV against influenza virus have been reported. The protective effect of KV against benzo[a]pyrene-induced reproductive and neurotoxicity has been documented. From our laboratory, we demonstrated the gastroprotective effect against sodium arsenite toxicity. KV has been reported to demonstrate a novel chemotherapeutic potential together with different pharmacological properties. Abarikwu et al. reported the anti-inflammatory effect of KV via inhibition of transcription factors ERK1/2, p-JNK, NF-κB, and activate Akt expression in the 93RS2 Sertoli cell lines. Oluwatosin et al. reported anti-malaria property of Kolaviron against Plasmodium berghei infection in Swiss albino mice. Adaramoye and Lawal reported cardio-protective effect against isoproterenol-induced injury by mitigating cardiac dysfunction and oxidative stress in rats.

2. Objectives

The present study was designed to investigate the ameliorative effect of KV against sodium arsenite-induced cardiorenal dysfunction and the underlying mechanism of action.

3. Materials and methods

3.1. Chemicals

Trichloroacetic acid, Ellman’s reagent (DTNB), NaAsO2, fetal calf serum, O-dianisidine, reduced glutathione (GSH), potassium dichromate, Hydrogen peroxide (H2O2), hydrochloric acid, sulphuric acid, xylene orange, sodium hydroxide, thiobarbituric acid (TBA), ammonium ferrous sulphate, potassium iodide, sodium potassium tartrate, copper sulphate, glacial acetic acid, ethanol, sodium azide, 2-dichloro-4-nitrobenzene (CDNB) and sorbitol were purchased from Sigma (St Louis, MO, USA). Normal goat serum, Biotinylated serum, Caspase 3 was purchased from (Bioss Inc. Woburn, Massachusetts, USA) while normal goat serum, Biotinylated serum, Caspase 3 was purchased from (AMRESCO LLC. OHio, USA). All other chemicals used were of analytical grade and obtained from British Drug Houses (Poole, Dorset, UK).

3.2. Extraction of G. kola and isolation of kolaviron (KV)

KV was extracted from the seeds of Garcinia kola according to the method of Iwu et al. The seeds were sliced, air-dried and ground to a fine powder using a pestle and mortar. The powdered seeds were defatted by extraction using n-hexane in a Soxhlet extractor apparatus for 24 h. The defatted dried marc was repackaged and extracted with methanol. KV was fractionated from concentrated methanol extract using chloroform to give Garcinia biflavanones-GB1, GB2 and kolaflavanone.

3.3. Experimental design and animal treatment

Forty male Wistar rats were obtained from the Experimental Animal Unit of Faculty of Veterinary Medicine, University of Ibadan, Nigeria and were randomly divided into four groups of ten animals per group. The animals were kept in wire mesh cages under controlled light cycle (12 h light/12 h dark) and fed with commercial rat chow ad libitum and liberally supplied with water.

Group A received normal saline. Group B received sodium arsenite at 10 mg/kg single dose intraperitoneally on day 7. Rats in Groups C and D were pre-treated orally with Kolaviron (KV) 100 mg/kg and 200 mg/kg for 7 days. The electrocardiograph (ECG) recording was taken on day 8 and the rats were sacrificed after the ECG measurement.

3.4. Care of animals

All the experimental animals received humane care according to the criteria outlined in the Guide for the Care and the Use of Laboratory Animals prepared by the National Academy of Science and published by the National Institute of Health. The ethics regulations were followed in accordance with national and institutional guidelines for the protection of the animals’ welfare during experiments according to Public health service.
3.5. Blood collection and serum preparation

Fresh whole blood (5 mls) was collected from each rat through the retro-orbital venous plexus into sterile plain tubes and left for about 30 min to clot. The clotted blood was thereafter centrifuged at 4,000 rpm for 10 min. Serum was harvested into sample bottles and stored at –20°C till the time of analysis.

3.6. Electrocardiogram (ECG) tracing

Standard lead II electrocardiogram was recorded in conscious rats using a 7-lead ECG machine (EDAN VE-1010, Shanghai, China). The machine was calibrated at 20 mm/mV paper speed and 50 mm/s paper speed. From the electrocardiogram, parameters such as heart rate, P-wave duration, PR-interval, QRS duration, R-amplitude, QT segment and Bazett’s correction of the QT interval were determined.

3.7. Biochemical assays

Cardiac and renal post mitochondrial fractions (PMFs) preparation for biochemical assays. The rats were sacrificed 24 h after the last administration. The heart and kidneys were removed, weighed and portion of it rinsed in 1.15% KCl and homogenized in potassium phosphate buffer (0.1 M, pH 7.4) and centrifuged at 12,000 g for 15 min to obtain the post mitochondria fractions (PMFs). The PMFs of the heart and the kidneys were obtained and subsequently stored at –20°C until the time of use.

3.7.1. Determination of cardiac and renal catalase (CAT) activity

Catalase (CAT) activity was determined according to the method of Sinha. Briefly, 1 ml portion from the reaction mixture 2 ml of H2O2 solution, 2.5 ml of 0.01 M potassium phosphate buffer (pH 7.0) and 1 ml of properly diluted PMF was blown into 1 ml dichromate/acidic acid solution by a gentle swirl at room temperature at 60 s interval for 3 times. The mixture was incubated in the water bath at 100 °C for 10 min. The absorbance was read at 570 nm using distilled water as blank. One unit of CAT activity represents the amount of enzyme required to decompose 1 μmol of H2O2/minute.

3.7.2. Determination of cardiac and renal superoxide dismutase (SOD) activity

Superoxide dismutase (SOD) activity was determined by the method of Misra and Fridovich with slight modification from our laboratory. Briefly, 100 mg of epinephrine was dissolved in 100 ml distilled water and acidified with 0.5 ml concentrated hydrochloric acid. This preparation prevents oxidation of epinephrine and is stable for 4 weeks. 0.01 ml of hemoglobin was added to 2.5 ml 0.05 M carbonate buffer (pH 10.2) followed by the addition of 0.3 ml of 0.3 mM adrenaline. The increase in absorbance at 480 nm was monitored every 30 s for 150 s. The reaction mixture was observed. The reaction mixture was subsequently incubated at room temperature for 30 min. The absorbance was measured against a blank of distilled water at 532 nm. Lipid peroxidation in units/mg protein was calculated with a molar extinction coefficient of 1.56 × 10^5 m^-1 cm^-1.

3.7.3. Determination of cardiac and renal reduced glutathione (GSH) activity

The content of hepatic reduced glutathione (GSH) was estimated by the method of Jollow et al. Briefly, 0.5 ml of 4% sulfosalicylic acid (precipitating agent) was added to 0.5 ml of PMF and centrifuged at 4,000 rpm for 5 min. To 0.5 ml of the resulting supernatant 4.5 ml of Ellman’s reagent (0.04 g of DTNB in 100 ml of 0.1M phosphate buffer, pH 7.4) was added. The absorbance was read at 412 nm against distilled water as blank.

3.7.4. Determination of cardiac and renal glutathione peroxidase (GPX) activity

The cardiac and renal glutathione peroxidase (GPX) activity was also measured according to Butetler et al. The reaction mixtures contain 0.5 ml of potassium phosphate buffer (pH 7.4), 0.1 ml of Sodium azide, 0.2 ml of GSH solution, 0.1 ml of H2O2, 0.5 ml of PMF and 0.6 ml of distilled water. The mixture was incubated in the water bath at 37 °C for 5 min and 0.5 ml of Trichloroacetic acid (TCA) was added and centrifuged at 4,000 rpm for 5 min 1 ml of the supernatant was taken and added to 2 ml of K2HPO4 and 1 ml of Ellman’s reagent. The absorbance was read at 412 nm using distilled water as blank.

3.7.5. Determination of glutathione-S-transferase (GST) activity

The activity of Glutathione-S-transferase (GST) was determined according the method of Habig et al. To 2.82 ml of 0.1M Potassium Phosphate buffer (pH 6.5), 150 μL of CDNB solution was added. Then, 30 μL of GSH solution was added to the reaction mixture together with 30 μL of PMFs of cardiac and renal tissues. The cuvette was quickly inverted; the increase in absorbance at 340 nm was monitored every 60 s for 150 s.

3.7.6. Determination of cardiac and renal thiobarbituric acid reactive substances (TBARS)

Thiobarbituric acid reactive substance was quantified as Malondialdehyde (MDA) in the cardiac and renal PMF. The MDA was determined according to the method of Varshney and Kala. To 1.6 ml of Tris–KCl, 0.5 ml of 30% TCA, 0.14 ml of samples and 0.5 ml of 0.75% Thiobarbituric acid (TBA) prepared in 0.2 M HCl were added. The reaction mixture was incubated in the water bath at 80 °C for 45 min, cooled on ice and centrifuged at 4,000 rpm for 15 min. The absorbance was measured against a blank of distilled water at 532 nm. Lipid peroxidation in units/mg protein was calculated with a molar extinction coefficient of 1.56 × 10^5 m^-1 cm^-1.

3.7.7. Measurement of cardiac and renal hydrogen peroxide (H2O2) generation

Hydrogen peroxide generation was determined according to the method of Wolffs. To 2.5 ml of 0.1M potassium phosphate buffer (pH 7.4), 0.250 ml of Ammonium ferrous sulphate (AFS), 0.1 ml of sorbitol, 0.1 ml of Xylenol Orange (XO), 0.025 ml of H2SO4 and 0.050 ml of cardiac and renal PMF were added. The mixture was mixed thoroughly by vortexing until a light pink colour of the reaction mixture was observed. The reaction mixture was subsequently incubated at room temperature for 30 min. The absorbance was measured at 560 nm using distilled water as blank. The hydrogen peroxide (H2O2) generated was extrapolated from hydrogen peroxide standard curve.

3.7.8. Determination of serum nitric oxide (NO) contents

The serum nitric oxide (NO) was measured as described by Olaleye et al. by indirectly measuring the nitrite concentration. After incubation at room temperature for 20 min, the absorbance at 540 nm was measured by spectrophotometer. The concentration of nitrite in the sample was determined from a sodium nitrite (NaNO2) standard curve and was expressed as μmol nitrite/mg protein.

3.7.9. Determination of serum myeloperoxidase activities

Myeloperoxidase (MPO) as marker of inflammation was measured according to the method of Xia and Zweier. To 2 ml of O-dianisidine mixture (16.7 mg of O-dianisidine, 100 ml of 0.05 M potassium phosphate buffer and 50 μL of diluted H2O2) put into the cuvette, 70 μL of serum was added. The increase in absorbance was measured at 460 nm.
monitored every 30 s for 1 min. The absorbance was read at 450 nm. One unit of MPO activity can be defined as the quantity of enzyme able to convert/degrade 1 μmol of hydrogen peroxide to water in 1 min at room temperature.

3.7.10. Determination of cardiac xanthine oxidase activity
The cardiac xanthine oxidase was determined according to the method of Akaeke et al.42 To 2, 950 μL of the substrate (xanthine-buffer) was added 50 μL of the post mitochondrial fraction (PMF) of the cardiac tissues making a total reaction mixture of 3,000 μL. The reaction mixture was prepared in duplicate and incubated for 40 min at room temperature. The reaction mixture was terminated with the addition of 100 μL of TCA at 0 min and 20 min respectively. The reaction mixture was centrifuged at 4,000 rpm for 20 min and the clear supernatants was read at 293 nm wavelengths.

3.7.11. Determination of serum enzymes and proteins
Determination of serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP). The activities of Aspartate aminotransferase (AST) and total bilirubin were determined using the Randox Kit (Randox Laboratories Limited, UK). The manufacturer instruction was followed in the assay protocol.

3.7.12. Determination of cardiac and renal protein determination
Protein concentrations were determined by means of the described by Gornal et al.43 Briefly, 1 ml of diluted serum was added to 3 ml of the biuret reagent. The reaction mixture was incubated at room temperature for 30 min. The mixture was thereafter read with spectrophotometer at 540 nm using distilled water as blank. The final value for total protein was extrapolated from total protein standard curve.

3.8. Immunohistochemistry of cardiac troponin I (CTnI), BCL2 and C-reactive proteins (CRP) cardiac and renal tissues
The paraffin-embedded heart and kidney tissues were placed on charged slides and then dewaxed by immersion in xylene for 5 min (twice). This was followed by dehydration in ethanol of 100%, 90% and 80% concentrations for 5 min each. The slides were placed in distilled water tank for 5 min before incubating with endogenous peroxidase for 10 min. After incubation, the slides were rinsed with water and placed in wash buffer tank for 5 min and then rinsed with distilled water. The slides were placed in citrate buffer tank at pH 6.0 (twice). This was followed by dehydration in ethanol of 100%, 90%, 80%, 90% and 100% ethanol for 3 min each after which they were transferred to xylene (100%) tank for 5 min (twice). The immunoreactive positive expression of cardiac troponin I (CTnI), BCL2 and C-reactive proteins (CRP) was observed on each slide under ×400 magnification with a digital microscope.

3.9. Histopathology
The heart and kidneys tissues were collected in 10% buffered formalin (pH 7.4) for proper fixation. These tissues were processed and embedded in paraffin wax. Sections of 5–6 μm in thickness were made and stained with haematoxylin and eosin for histopathological examination.44

3.10. Statistical analysis
All values are expressed as mean ± S.D. “One-way ANOVA with Dunnett’s post-test was also performed using GraphPad Prism version 4.00. The level of statistical significance was considered as p < 0.05.

4. Results

4.1. Serum nitric oxide and aminotransferases and phosphatase

Table 1 shows that NaAsO2 significantly (p < 0.05) increased serum ALT, AST and ALP when compared to the control or rats pretreated with KV (100 and 200 mg/kg), respectively. However, pretreatment with KV (100 and 200 mg/kg) significantly (p < 0.05) reduced serum ALT, AST and ALP activities. In another experiment, NaAsO2 intoxication led to a significant (p < 0.05) reduction in serum nitric oxide (NO) level relative the control and rats pretreated with KV as indicated in Table 1. The improvement in NO level (bioavailability) by KV was dose-dependent (Table 1).

4.2. Electrocardiogram (ECG)
From the present study, administration of NaAsO2 led to a significant (p < 0.05) increase in heart rate, QRS together with prolonged QT and QTc intervals in comparison with the control and rats administered with KV (100 and 200 mg/kg) (Table 2). On the other hand, pre-treatment with 100 and 200 mg/kg significantly lowered the heart rate, QRS and reversed the prolonged QT and QTc intervals (Table 2).

Table 1
| Parameters     | Control          | NaAsO2          | Kolaviron (100 mg/kg) | Kolaviron (200 mg/kg) |
|---------------|------------------|-----------------|----------------------|----------------------|
| ALT (U/L)     | 115.11±3.13      | 133.04±18.87    | 83.89±4.99           | 70.77±2.67           |
| AST (U/L)     | 158.00±0.37*     | 168.53±5.95*    | 133.00±7.44*         | 108.44±5.38*         |
| ALP (U/L)     | 358.80±26.46ab   | 427.80±19.51    | 386.40±39.03        | 294.40±31.87ab       |
| NO (μmol/mg protein) | 19.75±1.31ab     | 13.31±3.68b     | 15.17±4.21b         | 15.17±1.58ab         |

Group A (Control), Group B (NaAsO2), Group C (Kolaviron 100 mg/kg) and Group D (Kolaviron 200 mg/kg). Values are mean ± SD, n = 7, *P < 0.05 compared with control, **P < 0.05 compared with NaAsO2 alone.
4.3. Cardiac and renal markers of oxidative stress and antioxidant status

Fig. 1 shows that NaAsO₂ significantly \((p < 0.05)\) increased cardiac MDA contents and \(H_2O_2\) generation whereas KV (100 and 200 mg/kg) significantly \((p < 0.05)\) reduced these markers of oxidative stress. Similarly, the cardiac reduced glutathione (GSH) content declined in NaAsO₂ only treated rats compared to the control group and KV treated rats (Fig. 2). The activities of cardiac superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione-S-transferase (GST) and catalase (CAT) were significantly \((p < 0.05)\) reduced in animals administered NaAsO₂ alone relative to the control group and KV treated rats (Fig. 2). However, pre-treatment with KV (100 and 200 mg/kg) dose-dependently increased the activities of these antioxidants relative to the control group. In another experiment, a significant \((p < 0.05)\) increase in serum xanthine oxidase (XO) activity was obtained in rats administered NaAsO₂ alone (Fig. 3). However, the aforementioned increased serum XO activity was significantly inhibited by KV (100 and 200 mg/kg) pre-treatment.

The result obtained from this study showed that NaAsO₂ administration led to a significant \((p < 0.05)\) reduction in cardiac NO levels compared to the control or rats pre-treated with KV (100 and 200 mg/kg) as shown in Fig. 3. Interestingly, KV pre-treatment dose-dependently improved the cardiac NO level. Our data also showed a significant \((p < 0.05)\) increase in serum myeloperoxidase (MPO) activity in rats that received NaAsO₂ alone (Fig. 3). On the contrary, rats treated with KV showed a significant \((p < 0.05)\) reduction in MPO activity.

As indicated in Fig. 4, NaAsO₂ administration led to a significant \((p < 0.05)\) increase in renal MDA content and \(H_2O_2\) generation along with a significant \((p < 0.05)\) reduction in renal GSH (Fig. 4). In the same vein, KV treated rats showed significant \((p < 0.05)\) reduction in renal MDA content and \(H_2O_2\) generation together with significant improvement in renal GSH content (Fig. 4).

| Parameters | Control | NaAsO₂ | Kolaviron (100 mg/kg) | Kolaviron (200 mg/kg) |
|------------|---------|---------|-----------------------|-----------------------|
| Heart rate (Beats/mins) | 251.33 ± 13.61 | 495.00 ± 7.07<sup>a</sup> | 455.00 ± 26.46<sup>b</sup> | 490.00 ± 17.32<sup>ab</sup> |
| QRS (ms) | 17.25 ± 4.57 | 21.33 ± 3.51<sup>a</sup> | 15.25 ± 3.30<sup>b</sup> | 14.67 ± 2.06<sup>b</sup> |
| QT (ms) | 62.20 ± 9.25<sup>b</sup> | 71.67 ± 8.02<sup>a</sup> | 62.20 ± 9.25 | 63.50 ± 5.97 |
| QTc (ms) | 136.02 ± 12.70 | 198.61 ± 16.31<sup>a</sup> | 164.08 ± 19.71<sup>b</sup> | 172.23 ± 4.43<sup>ab</sup> |

Group A (Control), Group B (NaAsO₂), Group C (Kolaviron 100 mg/kg) and Group D (Kolaviron 200 mg/kg). Values are mean ± SD, \(n = 7\), \(aP < 0.05\) compared with control, \(bP < 0.05\) compared with NaAsO₂ alone.

**Table 2**

Effect of Sodium arsenite (NaAsO₂) on electrocardiogram (ECG).

**Fig. 1.** Effect of Kolaviron on cardiac reduced glutathione (GSH), hydrogen peroxide generation and malondialdehyde (MDA) in NaAsO₂ induced toxicity. Group A (Control), Group B (NaAsO₂), Group C (Kolaviron 100 mg/kg) and Group D (Kolaviron 200 mg/kg). Values are mean ± SD, \(n = 7\), \(aP < 0.05\) compared with control, \(bP < 0.05\) compared with NaAsO₂ alone.
Furthermore, NaAsO₂ intoxication caused a significant (p < 0.05) reduction in renal SOD, GPx, GST and CAT activities relative to the control and rats pre-treated with KV (100 and 200 mg/kg) as shown in Fig. 5. However, the activities of these antioxidant enzymes were reversed to near control values by KV pre-treatment in a dose-dependent manner. Also, NaAsO₂ administration led to a significant (p < 0.05) reduction in renal NO levels compared to the control or rats pre-treated with KV (100 and 200 mg/kg) whereas KV pre-treatment caused a significant improvement in the renal NO level as shown in Fig. 6. Again, a significant (p < 0.05) increase in kidney and heart weights in NaAsO₂ alone treated rats relative to the control and KV pre-treated rats (Fig. 7).

4.4. Immunohistochemical analysis of C-reactive protein (CRP), cardiac troponin I (CTnI) and BCL2

The immunohistochemistry revealed lower expressions of renal anti-apoptotic protein (BCL2) and higher expressions of C-reactive protein (CRP), respectively in NaAsO₂ alone treated rats (Figs. 8 and 9). However, KV (100 and 200 mg/kg) gave higher expressions of renal anti-apoptotic protein (BCL2) and lower expressions of CRP. In a similar experiment, higher expressions of immune-positive reactions of cardiac troponin I (CTnI) and cardiac CRP were observed in NaAsO₂ alone treated rats when compared with control and KV treated rats (Figs. 10 and 11).

4.5. Histology

The photomicrographs of renal tissues show severe inflammatory cells infiltration into the renal interstitium and periglomerular inflammation (Fig. 12). The photomicrographs of KV pre-treated rats however show mild inflammatory cells infiltration into the renal interstitium. Also, the photomicrographs of heart show inflammation of the pericardium and myocardium of the NaAsO₂ alone treated rats (Fig. 13). On the other hand, rats pre-treated with KV showed mild inflammation of the pericardium and myocardium with little cellular infiltration.

5. Discussion

The incidence of cardiovascular and renal dysfunction associated with environmental pollutants is becoming increasingly worrisome and a source of global concern. Associated with these environmental threats are clinical complications including hypertension, stroke, obesity, immune suppression, respiratory failure, cognitive disorders, developmental abnormality in children with resultant negative impact on the ecosystem health. Previous studies have recorded positive correlation between high levels of blood cadmium, mercury, lead and metabolic syndrome. Several studies have reported generation of reactive oxygen/nitrogen species (ROS/RNS) from exposure to environmental pollutants with resultant oxidative stress which have played a significant role in the mechanism of toxicity associated with heavy metals. Decrease in antioxidant defence system and with concomitant increase in ROS/RNS has become a biochemical yardstick in environmental pollutants-catalyzed oxidative stress reactions and chronic inflammation in vitro and in vivo. Results from the present study indicated that administration of NaAsO₂ precipitated significant increase in markers of oxidative stress and depletion of enzymic and non-enzymic antioxidant protection.
Fig. 3. Effect of Kolaviron on cardiac nitric oxide, serum myeloperoxidase (MPO) and xanthine oxidase (XO). Group A (Control), Group B (NaAsO₂), Group C (Kolaviron 100 mg/kg) and Group D (Kolaviron 200 mg/kg). Values are mean ± SD, n = 7, aP < 0.05 compared with control, bP < 0.05 compared with NaAsO₂ alone.

Fig. 4. Effect of Kolaviron on renal reduced glutathione (GSH), hydrogen peroxide generation and malondialdehyde (MDA) in NaAsO₂ induced toxicity. Group A (Control), Group B (NaAsO₂), Group C (Kolaviron 100 mg/kg) and Group D (Kolaviron 200 mg/kg). Values are mean ± SD, n = 7, aP < 0.05 compared with control, bP < 0.05 compared with NaAsO₂ alone.
status. Both cardiac and renal MDA levels and H$_2$O$_2$ generation increased whereas GPx, SOD, GST and CAT activities reduced significantly in NaAsO$_2$ only treated rats. Our study confirmed previous reports on the negative impact of environment pollutants on markers of antioxidants defense system and oxidative stress.\(^{56}\) However, KV pre-treatment modulated, reversed and reduced markers of oxidative stress together with apparent improvement in the antioxidant defense system.

The activity of serum XO was assessed in this study. The administration of NaAsO$_2$ increased the activity of serum XO which was indicative hyperuricemia. However, accumulating evidences have established positive correlation and remarkable association between hyperuricemia and oxidative stress, chronic heart failure, coronary artery, cerebrovascular disease, diabetes mellitus, metabolic syndrome and cardio-renal damage.\(^{59-61}\) Furthermore, hyperuricemia has been shown to increase free radicals generation that will ultimately damage cardiomyocytes and vascular endothelium together with disrupted myocardial contractility, arterial stiffness, endothelial dysfunction and vasoconstriction.\(^{62}\) Increase in the activity of XO is directly proportional to uric acid production. Therefore, Riegersperger et al.\(^ {63} \) reported that excessive uric acid might contribute significantly to the development of atherosclerosis, endothelial dysfunction, renovascular hyperten-
sion, and cardiovascular disease. It is worth to note that the increased activity of serum XO was reversed in the present study. In line with study, KV might be another novel antihyperuricemic agent and thereby open another therapeutic window as far as drug discovery, development and innovation in the field of science is concerned.

From the present study, the activity of serum Myeloperoxidase (MPO) activity increased significantly and this might due to NaAsO$_2$ intoxication. However, treatment of KV at the dose of 100 and 200 mg/kg decreased the serum MPO activity. This, therefore, might be indicative of anti-inflammatory and cardio-protective effect of KV. MPO has been found to be abundantly expressed in neutrophils and to a lesser extent in monocytes and some tissue macrophages.\(^ {64}\) In fact, recent report documented that macrophages are now used as an imaging biomarker in inflammatory cardiovascular diseases.\(^ {65} \) Several studies have suggested mechanistic links between myeloperoxidase, atherosclerosis, endothelial dysfunction, inflammation and are both acute and chronic manifestations of cardiovascular disease.\(^ {66,67} \) Together, KV could
therefore open a new therapeutic window for the treatment of atherosclerosis and other cardiovascular diseases.

Endothelial dysfunction and decreased NO levels have been found to have a positive correlation between oxidative stress and hypertension.\textsuperscript{68,69} Endothelial dysfunction has been reported to increase oxidative stress and reduce NO bioavailability.\textsuperscript{70,71} Our data showed that NaAsO\textsubscript{2} intoxication reduced NO bioavailability in the serum, cardiac and renal tissues. However, KV pre-treatment prior to NaAsO\textsubscript{2} intoxication significantly improved NO bioavailability. Further, we hypothesized that inhibition of SOD activity might also contribute to the development of hypertension through excessive generation of superoxide anion radicals which can mop-up NO leading to reduce NO bioavailability. Alternatively, peroxynitrite (ONOO\textsuperscript{−}) that is formed from the combination of NO and superoxide anion radical might also inhibit the endothelial nitric oxide synthase which is the key enzyme that produces NO from the endothelium for the maintenance of vascular tone and blood pressure. Similarly, KV might increase endothelial NO production, lower the systemic blood pressure, vasoconstriction, glomerular hypertension and arterial stiffness. Hence, KV could be a useful anti-hypertensive agent in the future.

The activities of serum ALT, AST and ALP were observed to have increased significantly in NaAsO\textsubscript{2} intoxicated rats. This is suggestive that apart from the cardio-renal dysfunction, hepatic injury could also be accompanied side-by-side in NaAsO\textsubscript{2} intoxication. Although, the increase in the activities of these enzymes along with other specific markers of cardiac damage have been reported in isoproterenol (ISO)-induced myocardial infarction (MI) in rats.\textsuperscript{72} Present study showed that in KV pre-treated rats, the increased activities of ALT, AST and ALP were restored compared to the control and the NaAsO\textsubscript{2} intoxicated rats.

The electrocardiogram (ECG) revealed increase heart rate, QRS together with prolonged QT and QTo intervals in NaAsO\textsubscript{2} intoxicated rats. Although, the increase in the activities of these enzymes along with other specific markers of cardiac damage have been reported in isoproterenol (ISO)-induced myocardial infarction (MI) in rats.\textsuperscript{72} Present study showed that in KV pre-treated rats, the increased activities of ALT, AST and ALP were restored compared to the control and the NaAsO\textsubscript{2} intoxicated rats.
intoxicated rats which is suggestive of negative influence of NaAsO₂ on cardiovascular system. Epidemiological studies have shown that chronic arsenic poisoning through ingestion of arsenic-contaminated water is associated with various cardiovascular diseases in dose-response relationship.⁷³ QT interval prolongation has been extensively documented in arsenic poisoning.⁷⁴–⁷⁶ The QT interval prolongation might be associated with increase in intracellular calcium overload as previously reported.⁷⁷ Hence, we propose that KV pre-treatment might have a modulatory effect on intracellular calcium current.

Fig. 9. The effect of Kolaviron on C-reactive protein (CRP) expressions in the Kidney in NaAsO₂ induced toxicity. Group A (Control), Group B (NaAsO₂), Group C (Kolaviron 100 mg/kg) and Group D (Kolaviron 200 mg/kg). Plates are stained with H and E stains and viewed with 100 objectives. The slides were counterstained with high definition hematoxylin and viewed × 100 objectives.

Fig. 10. The effect of Kolaviron on Cardiac Troponin I (CTnI) expressions in the heart in NaAsO₂ induced toxicity. Group A (Control), Group B (NaAsO₂), Group C (Kolaviron 100 mg/kg) and Group D (Kolaviron 200 mg/kg). The slides were counterstained with high definition hematoxylin and viewed × 100 objectives.
Our results indicated that rats intoxicated with NaAsO₂ had higher expressions of C-reactive protein (CRP), cardiac troponin I (CTnI) in the kidney and heart tissues, respectively. The CRP is a marker of inflammation whereas CTnI is a diagnostic marker of cardiac damage. Previous in vitro study on cardiac differentiation of rat myoblast H9c2 cell exposed to NaAsO₂ reported enhanced expression of cardiac troponin T (cTnT), the appearance of multinucleated cells, and cell cycle arrest at G0/G1 phase. Also, higher expressions of high sensitive C-reactive protein (hs-CRP) has also been reported in experimental animal models exposed to NaAsO₂ for 20 consecutive weeks with a resultant induction of arteriosclerosis.

The inflammatory reactions induced by NaAsO₂ intoxication in the kidney and heart was attenuated in KV pre-treated rats.
Increase inflammation and decrease in glomerular filtration rate (eGFR) following NaAsO₂ intoxication has also been reported⁸¹,⁸² and this is in line with the present study. The mechanism of arsenic acid-induced arteriosclerosis might be through induction of inflammation and oxidative stress. The anti-inflammatory, cardioprotective and nephroprotective effect of KV was therefore demonstrated through the inhibition of cardiac and renal CTnI and CRP, respectively. The BCL2 is a pro-survival and ant-apoptotic protein.⁸³ The involvement of BCL2 in cell survival, differentiation, autophagy and apoptosis cannot be undermined. However, KV pre-treated rats increased the expressions of BCL2 in the renal tissues, and this was indicative of nephron-protective effect of KV on NaAsO₂ intoxication renal damage. Our findings could therefore be supported from the work of Adil et al.⁸³ who reported the elevation of kidney marker injury 1 (KIM-1) and caspase 3 mRNA expression in rats exposed to NaAsO₂.

The histology of the kidney of rats administered NaAsO₂ alone showed cellular infiltration of renal interstitium and this was supported with increase in kidney weight of rats in the same group. The observed increase in the kidney weight might also be related to the inflammatory response elicited by NaAsO₂ as indicated with higher expressions of CRP. Furthermore, inflammation of the epicardium and pericardium together with increase heart weight was also observed in rats administrated NaAsO₂ without KV pre-treatment. In the KV pre-treated rats, the increase in kidney and heart weights combined with the pathology on the heart and kidney was restored.

6. Conclusion

In conclusion, KV may offer a new therapeutic regimen for the treatment of cardio-renal dysfunction associated with arteriosclerosis, hypertension and other cardiovascular dysfunctions. The administration of KV might also useful for the improvement of NO bioavailability which is necessary for the maintenance of vascular tone, blood pressure, improvement of coronary blood flow, vasodilation and prevention of arterial stiffness and vasoconstriction. Furthermore, the anti-inflammatory and cardio-renal protective effect of KV against NaAsO₂-induced inflammation and cardio-renal damage could be developed as novel drug for the amelioration of inflammation associated with cardiac and renal damage.

Conflict of interest

The authors declare that there are no conflicts of interest.

References

1. Manna P, Sinha M, Sil PC. Protection of arsenic-induced hepatic disorder by arjunolic acid. Basic Clin Pharmacol Toxicol. 2007;101(5):333–338.
2. Bustaffa E, Minichilli F, Andreassi MG, et al. Studies on markers of exposure and early effect in areas with arsenic pollution: methods and results of the project SEpiAs. Epidemiological surveillance in areas with environmental pollution by natural or anthropogenic arsenic. Epidemiol Prev. 2014;219(3–4 suppl 1):14–24.
3. Cubadda F, D’Amato M, Mancini FR, et al. Assessing human exposure to inorganic arsenic in high-arsenic areas of Latium: a biomonitoring study integrated with indicators of dietary intake. Ann Ig. 2015;27(1):39–51.
4. Bustaffa E, Bianchi F. Studies on markers of exposure and early effect in areas with arsenic pollution: methods and results of the project SEpiAs. Epidemiological studies on population exposed to low-to-moderate arsenic concentration in drinking water. Epidemiol Prev. 2014;38(3–4 suppl 1):14–24.
5. Hirano S, Kobayashi Y, Cui X, Kanno S, Hayakawa T, Shraim A. The accumulation and toxicity of methylated arsenicals in endothelial cells: important roles of thiol compounds. Toxicol Appl Pharmacol. 2004;198(3):458–467.
6. Jomova K, Jenisova Z, Fesztrova M, et al. Arsenic: toxicity, oxidative stress and human disease. J Appl Toxicol. 2011;31(2):95–107.
7. Hughes MF. Biomarkers of exposure: a case study with inorganic arsenic. Environ Health Perspect. 2006;114(11):1790–1796.
8. Ghosh J, Das J, Manpa P, Sil PC. Taurine prevents arsenic-induced cardiac oxidative stress and apoptotic damage: role of NF-kappa B, p38 and JNK MAPK pathway. Toxicol Appl Pharmacol. 2009;240(1):73–87.
9. Fu S, Wu J, Li Y, et al. Urinary arsenic metabolism in a Western Chinese population exposed to high-dose inorganic arsenic in drinking water: influence of ethnicity and genetic polymorphisms. Toxicol Appl Pharmacol. 2014;274(1):117–123.
10. Das AK, Bag S, Sahu R, et al. Protective effect of Corchorus olitorius leaves on sodium arsenite-induced toxicity in experimental rats. Food Chem Toxicol. 2010;48(1):326–335.
11. Manna P, Sinha M, Sil PC. Arsenic-induced oxidative myocardial injury: protective role of arjunolic acid. Arch Toxicol. 2008;82(3):137–149.
13. Liu J, Liang SX, Lu GP, Wu Q, Shi JS. Realgar and realgar-containing hepatotoxic metabolite in Wistar rats. J Biol Chem 1972;217:3170–3175.

14. Oyagbemi AA, Adegbija JO, Adaramoye OA, Lawal SO. Effect of Kolaviron, a bi...antioxidant activity in the autoxidation of lipids in microsomes. Toxicol Lett 1994;71:131–137.

15. Adaramoye OA, Lawal SO. Kolaviron, a bi...n patients. Toxicon 2016;98:111–118.

16. Awogbini IO, Adeyelo DE, Farombi EO. Kolaviron improves morbidity and suppresses mortality by mitigating oxidant-inflammation in BALB/c mice infected with influenza virus. Viral Immunol 2015;28(7):367–377.

17. Oluwatosin A, Tolulope A, Ayokulehin K, et al. Antimalarial potential of Kola...infection in Swiss albino mice. Asian Pac J Trop Med 2014;46(8):878–884.

18. Owoeye O, Adedara IA, Ademuyiwa EO, Bakare OS, Adeyemo OA, Egun C, Farombi EO. Kolaviron scavenges superoxide anion radicals and protects against renal dysfunction and renal morphology changes in diabetic nephropathy. Ren Fail 2015;37(1):3–13.

19. Liu J, Liang SX, Lu GP, Wu Q, Shi JS. Realgar and realgar-containing hepatotoxic metabolite in Wistar rats. J Biol Chem 1972;217:3170–3175.

20. Oluwatosin A, Tolulope A, Ayokulehin K, et al. Antimalarial potential of Kola...infection in Swiss albino mice. Asian Pac J Trop Med 2014;46(8):878–884.

21. Owoeye O, Adedara IA, Bakare OS, Adeyemo OA, Egun C, Farombi EO. Kolaviron scavenges superoxide anion radicals and protects against renal dysfunction and renal morphology changes in diabetic nephropathy. Ren Fail 2015;37(1):3–13.

22. Ayepola OR, Cerf ME, Brooks NL, Oguntibeju OO. Kolaviron, a bi...human tissues. Measurement of myeloperoxidase in leukocyte-containing tissues. Methods Enzymol 1994;255:1–53.

23. Owoeye O, Adedara IA, Bakare OS, Adeyemo OA, Egun C, Farombi EO. Kolaviron scavenges superoxide anion radicals and protects against renal dysfunction and renal morphology changes in diabetic nephropathy. Ren Fail 2015;37(1):3–13.

24. Abarikwu SO. Kolaviron, a natural...epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1940;177:751–766.

25. Adaramoye OA, Arisekola M. Kolaviron, a bi...infusion in the gastric mucosa of HCl/ethanol-exposed rats. Food Chem Toxicol 2011;49(4):1375–1383.

26. Awogbini IO, Adeyelo DE, Farombi EO. Kolaviron improves morbidity and suppresses mortality by mitigating oxidant-inflammation in BALB/c mice infected with influenza virus. Viral Immunol 2015;28(7):367–377.

27. Oluwatosin A, Tolulope A, Ayokulehin K, et al. Antimalarial potential of Kola...infection in Swiss albino mice. Asian Pac J Trop Med 2014;46(8):878–884.

28. Adaramoye OA, Lawal SO. Kolaviron, a bi...n patients. Toxicon 2016;98:111–118.

29. Oluwatosin A, Tolulope A, Ayokulehin K, et al. Antimalarial potential of Kola...infection in Swiss albino mice. Asian Pac J Trop Med 2014;46(8):878–884.

30. Liu J, Liang SX, Lu GP, Wu Q, Shi JS. Realgar and realgar-containing hepatotoxic metabolite in Wistar rats. J Biol Chem 1972;217:3170–3175.

31. Shinh KA. Colorimetric assay of catalase. Anal Biochem 1972;47:389–394.

32. Misra HP, Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972;217:3170–3175.

33. Oyagbemi AA, Omobowale AO, Akinrinde AS, Saba AB, Ogunpolu BS, Oyagbemi AA, Omobowale AO, Akinrinde AS, Saba AB, Ogunpolu BS. Improved method for the determination of blood acetaldehyde. Environ Res 2013;125:66–72.

34. Liu J, Liang SX, Lu GP, Wu Q, Shi JS. Realgar and realgar-containing hepatotoxic metabolite in Wistar rats. J Biol Chem 1972;217:3170–3175.

35. Gornal AG, Bardwaj IC, Dawsey DM. Determination of serum proteins by means of a biuret reaction. J Biol Chem 1949;177:719–726.

36. Buettner G, Duron O, Kelly BM. Improved method for the determination of blood acetaldehyde. Environ Res 2013;125:66–72.

37. Habig WH, Pabst MJ, Jacoby WB. Glutathione-S-transferase activity: the...of glutathione. J Biol Chem 1972;177:3170–3175.

38. Wolff SF. Ferrous ion oxidation in the presence of ferric ion indicator xanthenol orange for measurement of hydrogen peroxides. Methods Enzymol 1994;233:182–189.

39. Olaye SJ, Amudan AY, Adegbija JO, Farombi EO. Kolaviron protects against ischemia/reperfusion injury: pertinent mechanistic insights from biochemical and physical evaluations in rat brain. Neurochem Res 2015;40(4):777–787.

40. Olaye SJ, Amudan AY, Adegbija JO, Farombi EO. Kolaviron protects against ischemia/reperfusion injury: pertinent mechanistic insights from biochemical and physical evaluations in rat brain. Neurochem Res 2015;40(4):777–787.

41. Abarikwu SO. Kolaviron, a natural...inflammation in diabetes-induced nephrotoxic rats. PLoS ONE 2013;28(1):9–16.

42. Olaye SJ, Amudan AY, Adegbija JO, Farombi EO. Kolaviron protects against ischemia/reperfusion injury: pertinent mechanistic insights from biochemical and physical evaluations in rat brain. Neurochem Res 2015;40(4):777–787.
69. Islam MZ, Van Dao C, Shiraishi M, Miyamoto A. Methylmercury affects cerebrovascular reactivity to angiotensin II and acetylcholine via Rho-kinase and nitric oxide pathways in mice. Life Sci. 2016;147:30–38.

70. Molina MN, Ferder L, Manucha W. Emerging role of nitric oxide and heat shock proteins in insulin resistance. Curr Hypertens Rep. 2016;18(1), 1.

71. Kao CK, Morton JS, Quon AL, Reyes LM, Lopez-Jaramillo P, Davidge ST. Mechanism of vascular dysfunction due to circulating factors in women with pre-eclampsia. Clin Sci (Lond). 2016;130(7):539–549.

72. Geng ZH, Huang L, Song MB, Song YM. Protective effect of a polysaccharide from Salvia miltiorrhiza on isoproterenol (ISO)-induced myocardial injury in rats. Carbohydr Polym. 2015;132:638–642.

73. Wang CH, Hsiao CK, Chen CL, et al. A review of the epidemiologic literature on the role of environmental arsenic exposure and cardiovascular diseases. Toxicol Appl Pharmacol. 2007;222(3):315–326.

74. Chen X, Shan H, Zhao J, et al. L-type calcium current (ICa,L) and inward rectifier potassium current (IK1) are involved in QT prolongation induced by arsenic trioxide in rat. Cell Physiol Biochem. 2010;26(6):967–974.

75. Liao YT, Li WF, Chen CJ, et al. Synergistic effect of polymorphisms of paraoxonase gene cluster and arsenic exposure on electrocardiogram abnormality. Toxicol Appl Pharmacol. 2009;239(2):178–183.

76. Zhao XY, Li GY, Liu Y, et al. Resveratrol protects against arsenic trioxide-induced cardiotoxicity in vitro and in vivo. Br J Pharmacol. 2008;154(1):165–113.

77. Fan Y, Wang C, Zhang Y, et al. Genistein ameliorates adverse cardiac effects induced by arsenic trioxide through preventing cardiomyocytes apoptosis. Cell Physiol Biochem. 2013;31(1):90–91.

78. Sumi D, Abe K, Himeno S. Arsenite retards the cardiac differentiation of rat cardiac myoblast H9c2 cells. Biochem Biophys Res Commun. 2013;436(2):175–179.

79. Cheng TJ, Chiu JJ, Chang CY, Tsai WC, Chen KJ, Guo HR. Atherosclerosis induced by arsenic in drinking water in rats through altering lipid metabolism. Toxicol Appl Pharmacol. 2011;256(2):146–153.

80. Peters BA, Hall MN, Liu X, et al. Renal function is associated with indicators of arsenic methylation capacity in Bangladeshi adults. Environ Res. 2015;143(Pt A):123–130.

81. Kesavan M, Sarath TS, Kannan K, et al. Atorvastatin restores arsenic-induced vascular dysfunction in rats: modulation of nitric oxide signaling and inflammatory mediators. Toxicol Appl Pharmacol. 2014;280(1):107–116.

82. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell. 2010;37(1):299–310.

83. Adil M, Kandhare AD, Visnagri A, Bodhankar SL. Naringin ameliorates sodium arsenite-induced renal and hepatic toxicity in rats: decisive role of KIM-1, Caspase-3, TGF-β, and TNF-α. Ren Fail. 2015;37(8):1396–1407.